Navigation Links
Indivumed Sells Inostics, the plasma-DNA Company, to Sysmex and Expands its Clinical Research Service and Patient Diagnostics Business
Date:9/25/2013

HAMBURG, Germany, September 25, 2013 /PRNewswire/ --

Indivumed GmbH ("Indivumed"), based in Hamburg, Germany, announces that 100% of all shares of Inostics GmbH and its Baltimore, US-based subsidiary Inostics Inc. ("Inostics"), have been sold to Sysmex Corporation (Headquarter in Kobe, Japan).

Inostics possesses advanced genetic testing technologies, such as ultra-sensitive digital PCR technology for detecting cancer cell DNA directly from blood - a "liquid biopsy" process as opposed to tissue testing. By acquiring this technology, Sysmex plans to develop on a global basis assay services that Inostics already provides. Sysmex's companion diagnostics activities in collaboration with pharmaceutical companies will be enhanced as well.

In 2008, following a five year collaboration with Dr. Bert Vogelstein and his team at Johns Hopkins University in Baltimore, MD, Indivumed and the scientists at Johns Hopkins University together founded Inostics GmbH in Hamburg, Germany, to commercialize the "BEAMing-Technology". "Having established a solid foundation to enable the rapid growth of Inostics, the overwhelming acceptance of this groundbreaking technology by pharmaceutical companies and the medical community demanded a global growth strategy and search for a strategic partner. We are delighted to have found with Sysmex the ideal partner for the next development phase," comments Prof. Hartmut Juhl, CEO of Indivumed and Inostics.

"With Sysmex, we expect achieving our goal to make Inostics technology the leading approach for DNA-based cancer diagnostics for the worldwide benefit of cancer patients. The fact that Sysmex has its European Headquarter in the Hamburg area facilitates a smooth transition and an undelayed continuation of Inostics business" says Dr. Frank Diehl, co-founder of Inostics, who continues to work for Inostics as Chief Scientific Officer and Managing Director.

Following the closing of the transaction, Indivumed will independently expand its tissue-based clinical research service business leveraging a comprehensive and very high quality tumor-biobank and its well-established prowess in the analysis of proteins and cancer pathways for drug development and patient diagnostics.

JMP Securities LLC acted as financial advisor and Freshfields Bruckhaus Deringer LLP served as legal counsel to Inostics and its shareholder in the transaction.

About Indivumed GmbH

Indivumed GmbH, a privately hold biotech company, was founded 2002 in Hamburg, Germany, to promote the development and clinical implementation of individual cancer therapies. Based on a highly standardized tumor biobank and a unique clinical infrastructure with clinical partners in Germany and the US, Indivumed offers a broad range of specialized research services to biopharmaceutical companies and academia and performs biomarker research and development. With its subsidiary IndivuTest GmbH, Indivumed provides high-quality-tissue based tumor analysis to patients and started an initiative with oncologists in Germany and the US to improve personalized cancer therapy strategies in the clinical routine.

For more information (also about Inostics and IndivuTest) please visit http://www.indivumed.com.

About Sysmex Corporation

Sysmex Corporation (Headquarter: Kobe, Japan), a listed company at the Tokyo Stock Exchange market, supports human health. Sysmex is an integrated company, developing and manufacturing the instruments, reagents and software that are needed for in-vitro diagnostics, and providing the necessary sales and support networks. Sysmex is expanding operations, augmenting traditional strength in hematology with non-hematology fields such as immunochemistry and hemostasis, as well as the life science field. Sysmex is leveraging its proprietary technologies to create new testing and diagnostic technologies that aim to ensure optimal healthcare for all.

For more information please visit http://www.sysmex.com.

Press contact:
Swantje Niphut
E-Mail: press@indivumed.com
Phone: +49(0)40-413383-0



'/>"/>
SOURCE Indivumed GmbH
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Geisinger Partners With Indivumed for Personalized Medicine Initiative
2. Pure Garcinia Cambogia Extract from Zen Health Labs Sells Out Three Weeks after its Launch on Amazon
3. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
4. Microsofts Surface Pro Tablet Makes its Debut and Sells Out Fast; the Company was One of the Few to Defy the Dows Loss Yesterday
5. Apama Medical, A Shifamed Portfolio Company, Closes $3.2M Series A-1 Financing Round
6. ParagonRx, An inVentiv Health Company, Names Former U.S. Food And Drug Administration Official To Position Of Chief Medical Officer
7. Pioneering Medical Technology Company, Optivus Proton Therapy, Inc., Celebrates 20th Anniversary
8. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
9. Nucletron, an Elekta company, to Debut New Flexitron Brachytherapy Afterloading Platform at 2013 American Brachytherapy Society Meeting
10. Accordant Health Services, a CVS Caremark Company, Receives URAC Case Management Accreditation
11. PrimerLife.com, a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology:
(Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):